Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.
[EN] HIV PROTEASE INHIBITORS AND METHODS FOR USING<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH ET PROCÉDÉS D'UTILISATION
申请人:PURDUE RESEARCH FOUNDATION
公开号:WO2010006050A1
公开(公告)日:2010-01-14
Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.
Flexible Cyclic Ethers/Polyethers as Novel P2-Ligands for HIV-1 Protease Inhibitors: Design, Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies
作者:Arun K. Ghosh、Sandra Gemma、Abigail Baldridge、Yuan-Fang Wang、Andrey Yu. Kovalevsky、Yashiro Koh、Irene T. Weber、Hiroaki Mitsuya
DOI:10.1021/jm8004543
日期:2008.10.9
biological evaluation of a series of novel HIV-1proteaseinhibitors. The inhibitors incorporate stereochemically defined flexible cyclic ethers/polyethers as high affinity P2-ligands. Inhibitors containing small ring 1,3-dioxacycloalkanes have shown potent enzyme inhibitory and antiviral activity. Inhibitors 3d and 3h are the most active inhibitors. Inhibitor 3d maintains excellent potency against a
我们报告了一系列新型 HIV-1 蛋白酶抑制剂的设计、合成和生物学评估。抑制剂包含立体化学定义的柔性环醚/聚醚作为高亲和力 P2 配体。含有小环 1,3-二氧杂环烷烃的抑制剂已显示出有效的酶抑制和抗病毒活性。抑制剂 3d 和 3h 是活性最强的抑制剂。Inhibitor 3d 对多种多重 PI 抗性临床菌株保持出色的效力。我们的构效研究表明,环的大小、立体化学和氧的位置对观察到的活性很重要。已经描述了 1,3-dioxepan-5-ol 的光学活性合成以及各种环醚和聚醚配体的合成。确定了 3d 结合的 HIV-1 蛋白酶的蛋白质配体 X 射线晶体结构。该结构表明,P2-配体进行广泛的相互作用,包括与 S2 位点中的蛋白酶骨架形成氢键。此外,3d 中的 P2-配体与 Gly-48 的 NH 形成独特的水介导的相互作用。
HIV PROTEASE INHIBITORS AND METHODS FOR USING
申请人:Ghosh Arun K.
公开号:US20110118330A1
公开(公告)日:2011-05-19
Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.